Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 43 | 2024 | 3187 | 5.100 |
Why?
|
Kidney Neoplasms | 44 | 2024 | 4282 | 4.570 |
Why?
|
Carcinoma, Transitional Cell | 14 | 2024 | 794 | 3.810 |
Why?
|
Urinary Bladder Neoplasms | 16 | 2024 | 2195 | 2.520 |
Why?
|
Urologic Neoplasms | 8 | 2024 | 314 | 1.820 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11878 | 1.710 |
Why?
|
Immunoconjugates | 4 | 2023 | 975 | 1.410 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 130 | 1.240 |
Why?
|
Penile Neoplasms | 2 | 2021 | 158 | 1.210 |
Why?
|
Anilides | 6 | 2022 | 413 | 1.110 |
Why?
|
Immunotherapy | 11 | 2024 | 4755 | 0.770 |
Why?
|
Urinary Tract | 1 | 2024 | 305 | 0.700 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.680 |
Why?
|
Antibodies, Monoclonal | 6 | 2023 | 9263 | 0.640 |
Why?
|
Nephrectomy | 3 | 2022 | 930 | 0.610 |
Why?
|
Pyridines | 6 | 2022 | 2894 | 0.600 |
Why?
|
Bone Diseases | 1 | 2020 | 416 | 0.540 |
Why?
|
Testicular Neoplasms | 2 | 2019 | 806 | 0.520 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 4058 | 0.450 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 498 | 0.450 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 797 | 0.420 |
Why?
|
Radiotherapy | 1 | 2019 | 1502 | 0.410 |
Why?
|
Medical Oncology | 1 | 2023 | 2346 | 0.380 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2914 | 0.380 |
Why?
|
Neoplasm Metastasis | 9 | 2023 | 4912 | 0.360 |
Why?
|
Humans | 90 | 2024 | 768166 | 0.340 |
Why?
|
Arabinonucleosides | 1 | 2009 | 34 | 0.320 |
Why?
|
Adenine Nucleotides | 1 | 2009 | 110 | 0.320 |
Why?
|
Buttocks | 1 | 2009 | 111 | 0.310 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13676 | 0.310 |
Why?
|
Sarcoma | 1 | 2019 | 1806 | 0.300 |
Why?
|
Lymph Nodes | 1 | 2019 | 3474 | 0.290 |
Why?
|
Neoplasm Staging | 8 | 2024 | 11244 | 0.290 |
Why?
|
Aged, 80 and over | 21 | 2024 | 59629 | 0.280 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 230 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5703 | 0.270 |
Why?
|
Male | 53 | 2024 | 364719 | 0.270 |
Why?
|
Aneurysm, False | 1 | 2009 | 263 | 0.260 |
Why?
|
Tissue and Organ Harvesting | 1 | 2009 | 373 | 0.250 |
Why?
|
Androgen Antagonists | 3 | 2023 | 1412 | 0.250 |
Why?
|
Middle Aged | 39 | 2024 | 223492 | 0.250 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6395 | 0.250 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 384 | 0.240 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2009 | 646 | 0.240 |
Why?
|
Fatigue | 2 | 2022 | 1557 | 0.230 |
Why?
|
Rare Diseases | 2 | 2020 | 631 | 0.230 |
Why?
|
Prostatic Neoplasms | 6 | 2023 | 11101 | 0.230 |
Why?
|
Cyclophosphamide | 4 | 2021 | 2227 | 0.230 |
Why?
|
Cell Adhesion Molecules | 2 | 2021 | 1613 | 0.230 |
Why?
|
Cystectomy | 3 | 2024 | 603 | 0.220 |
Why?
|
Aged | 34 | 2024 | 171504 | 0.220 |
Why?
|
Radium | 1 | 2024 | 70 | 0.220 |
Why?
|
Doxorubicin | 4 | 2021 | 2234 | 0.210 |
Why?
|
Vinblastine | 2 | 2021 | 487 | 0.210 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2907 | 0.210 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 8054 | 0.200 |
Why?
|
Salvage Therapy | 1 | 2009 | 1273 | 0.200 |
Why?
|
Phenylthiohydantoin | 2 | 2022 | 207 | 0.200 |
Why?
|
Brain Neoplasms | 2 | 2022 | 9118 | 0.190 |
Why?
|
Neoplasm Invasiveness | 3 | 2024 | 3620 | 0.190 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2023 | 3514 | 0.190 |
Why?
|
Nutrition Disorders | 1 | 2022 | 204 | 0.190 |
Why?
|
Bone Marrow Cells | 1 | 2009 | 2414 | 0.190 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 531 | 0.190 |
Why?
|
Organoplatinum Compounds | 2 | 2019 | 408 | 0.180 |
Why?
|
Benzoxazoles | 1 | 2022 | 92 | 0.180 |
Why?
|
Treatment Outcome | 15 | 2024 | 65371 | 0.180 |
Why?
|
Cisplatin | 3 | 2021 | 1660 | 0.180 |
Why?
|
Chorionic Gonadotropin | 1 | 2023 | 458 | 0.180 |
Why?
|
Adult | 29 | 2024 | 223646 | 0.180 |
Why?
|
Methotrexate | 3 | 2023 | 1721 | 0.180 |
Why?
|
Platinum | 1 | 2022 | 222 | 0.180 |
Why?
|
Watchful Waiting | 1 | 2024 | 492 | 0.170 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 1515 | 0.170 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.170 |
Why?
|
Prognosis | 9 | 2022 | 30010 | 0.170 |
Why?
|
Deoxycytidine | 2 | 2021 | 887 | 0.170 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 257 | 0.170 |
Why?
|
Genetic Counseling | 1 | 2023 | 635 | 0.160 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 164 | 0.160 |
Why?
|
Endocrine System Diseases | 1 | 2021 | 250 | 0.160 |
Why?
|
Angiogenesis Inhibitors | 4 | 2023 | 2056 | 0.160 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 325 | 0.160 |
Why?
|
Quinolines | 1 | 2024 | 772 | 0.160 |
Why?
|
Retrospective Studies | 21 | 2024 | 81762 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 211 | 0.160 |
Why?
|
Nitriles | 2 | 2022 | 980 | 0.150 |
Why?
|
Thyroid Diseases | 1 | 2022 | 385 | 0.150 |
Why?
|
Kidney Pelvis | 1 | 2019 | 191 | 0.150 |
Why?
|
Benzamides | 2 | 2022 | 1379 | 0.150 |
Why?
|
Female | 34 | 2024 | 397192 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2022 | 8647 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2022 | 8542 | 0.140 |
Why?
|
Leucovorin | 1 | 2019 | 643 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 614 | 0.140 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1667 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 596 | 0.140 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.140 |
Why?
|
Obesity | 1 | 2019 | 13090 | 0.130 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11095 | 0.130 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2023 | 1942 | 0.130 |
Why?
|
Quality of Life | 3 | 2023 | 13490 | 0.130 |
Why?
|
Bayes Theorem | 1 | 2023 | 2359 | 0.120 |
Why?
|
Autoantibodies | 1 | 2024 | 2121 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1320 | 0.120 |
Why?
|
Molecular Targeted Therapy | 3 | 2024 | 2830 | 0.120 |
Why?
|
Neck | 1 | 2019 | 736 | 0.120 |
Why?
|
Fluorouracil | 1 | 2019 | 1652 | 0.110 |
Why?
|
Eligibility Determination | 1 | 2018 | 421 | 0.110 |
Why?
|
Tumor Burden | 1 | 2020 | 1906 | 0.110 |
Why?
|
Neutrophils | 4 | 2022 | 3786 | 0.110 |
Why?
|
Lymphocytes | 2 | 2022 | 2614 | 0.110 |
Why?
|
Oligopeptides | 1 | 2019 | 1194 | 0.110 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4648 | 0.110 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3948 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1613 | 0.110 |
Why?
|
Young Adult | 10 | 2024 | 60066 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2022 | 1536 | 0.110 |
Why?
|
Disease-Free Survival | 5 | 2024 | 6847 | 0.110 |
Why?
|
Gastrointestinal Diseases | 1 | 2021 | 1206 | 0.110 |
Why?
|
Forecasting | 2 | 2019 | 2945 | 0.100 |
Why?
|
Breast Neoplasms, Male | 1 | 2014 | 213 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2227 | 0.100 |
Why?
|
Anemia | 1 | 2022 | 1514 | 0.100 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 747 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1885 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3556 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1596 | 0.100 |
Why?
|
Pyrazoles | 1 | 2022 | 2028 | 0.090 |
Why?
|
Prospective Studies | 4 | 2024 | 54926 | 0.090 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4206 | 0.090 |
Why?
|
Survival Rate | 3 | 2020 | 12840 | 0.080 |
Why?
|
Patient Selection | 2 | 2019 | 4260 | 0.080 |
Why?
|
Carcinoma | 1 | 2021 | 2332 | 0.080 |
Why?
|
Pyrimidines | 1 | 2022 | 3048 | 0.080 |
Why?
|
Idarubicin | 1 | 2009 | 59 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1883 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2024 | 6526 | 0.080 |
Why?
|
Filgrastim | 1 | 2009 | 131 | 0.080 |
Why?
|
Mitoxantrone | 1 | 2009 | 148 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1942 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1447 | 0.080 |
Why?
|
Biopsy | 2 | 2019 | 6793 | 0.080 |
Why?
|
Vidarabine | 1 | 2009 | 337 | 0.070 |
Why?
|
Survival Analysis | 5 | 2021 | 10101 | 0.070 |
Why?
|
Drug Evaluation | 1 | 2009 | 642 | 0.070 |
Why?
|
Etoposide | 1 | 2009 | 639 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9374 | 0.070 |
Why?
|
Cytarabine | 1 | 2009 | 695 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2023 | 39348 | 0.070 |
Why?
|
Pain | 1 | 2022 | 5100 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2018 | 1640 | 0.070 |
Why?
|
Vincristine | 1 | 2009 | 1040 | 0.070 |
Why?
|
Cell Line, Tumor | 1 | 2023 | 17140 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 631 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13671 | 0.060 |
Why?
|
Genomics | 1 | 2021 | 5926 | 0.060 |
Why?
|
Dementia | 1 | 2019 | 2740 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13290 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2009 | 1836 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 13014 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40218 | 0.060 |
Why?
|
Androgens | 2 | 2023 | 1281 | 0.060 |
Why?
|
Intention to Treat Analysis | 1 | 2024 | 416 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5367 | 0.050 |
Why?
|
Remission Induction | 1 | 2009 | 2410 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5432 | 0.050 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 168 | 0.050 |
Why?
|
Glutaminase | 1 | 2022 | 31 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9419 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7454 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 30238 | 0.050 |
Why?
|
United States | 2 | 2020 | 73039 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2023 | 277 | 0.050 |
Why?
|
Dexamethasone | 1 | 2009 | 1965 | 0.050 |
Why?
|
Genealogy and Heraldry | 1 | 2021 | 29 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2014 | 10760 | 0.050 |
Why?
|
Glutamates | 1 | 2022 | 385 | 0.050 |
Why?
|
Body Mass Index | 1 | 2019 | 13053 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7477 | 0.040 |
Why?
|
Vaccinia virus | 1 | 2022 | 328 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 345 | 0.040 |
Why?
|
Androstenes | 1 | 2022 | 177 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2022 | 15832 | 0.040 |
Why?
|
Glutamine | 1 | 2022 | 577 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9538 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6514 | 0.040 |
Why?
|
Penetrance | 1 | 2021 | 385 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 371 | 0.040 |
Why?
|
Urothelium | 1 | 2021 | 275 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3671 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 472 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 899 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 802 | 0.040 |
Why?
|
Reoperation | 1 | 2009 | 4329 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 560 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 598 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 905 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 710 | 0.040 |
Why?
|
Tissue Extracts | 1 | 2017 | 139 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 879 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 465 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 794 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 737 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2024 | 1065 | 0.040 |
Why?
|
Haemophilus influenzae | 1 | 1997 | 177 | 0.040 |
Why?
|
Muscle, Smooth | 1 | 2021 | 931 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13586 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1155 | 0.030 |
Why?
|
Recurrence | 1 | 2009 | 8509 | 0.030 |
Why?
|
Hospital Costs | 1 | 2022 | 957 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1997 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2018 | 684 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1008 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20760 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2021 | 1157 | 0.030 |
Why?
|
Polysaccharides, Bacterial | 1 | 1997 | 582 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4030 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1627 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1493 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2018 | 1609 | 0.030 |
Why?
|
Amyloidosis | 1 | 2001 | 878 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12543 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22371 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 892 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1918 | 0.020 |
Why?
|
Streptococcus pneumoniae | 1 | 1997 | 764 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36743 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2024 | 2565 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2744 | 0.020 |
Why?
|
Animals | 2 | 2022 | 169246 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2009 | 5717 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2810 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3467 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2001 | 2100 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1997 | 2709 | 0.020 |
Why?
|
Artifacts | 1 | 2018 | 1926 | 0.020 |
Why?
|
Cohort Studies | 3 | 2020 | 41754 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12465 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21206 | 0.020 |
Why?
|
Paclitaxel | 1 | 2014 | 1733 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7608 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7876 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4852 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4860 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5799 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5315 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2001 | 3781 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 1997 | 4568 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8741 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11669 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10399 | 0.010 |
Why?
|
Adolescent | 3 | 2021 | 89169 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9615 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 74944 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15454 | 0.010 |
Why?
|
Pulse Therapy, Drug | 1 | 2001 | 37 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12168 | 0.010 |
Why?
|
Serum Amyloid A Protein | 1 | 2001 | 128 | 0.010 |
Why?
|
Depression | 1 | 2019 | 8230 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18065 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2001 | 1377 | 0.010 |
Why?
|
Cerebrospinal Fluid Proteins | 1 | 1979 | 71 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42669 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23645 | 0.010 |
Why?
|
Neuromuscular Diseases | 1 | 1979 | 260 | 0.010 |
Why?
|
Bacterial Vaccines | 1 | 1997 | 400 | 0.010 |
Why?
|
Vaccines, Synthetic | 1 | 1997 | 622 | 0.010 |
Why?
|
Motor Neurons | 1 | 1979 | 870 | 0.010 |
Why?
|
Child | 1 | 2021 | 80917 | 0.010 |
Why?
|
Age Factors | 1 | 1979 | 18412 | 0.000 |
Why?
|